EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Novadaq Technologies's enterprise value is $660.94 Mil.
Novadaq Technologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2017 was $-45.41 Mil. Therefore, Novadaq Technologies's EV-to-EBITDA for today is -14.55.
The historical rank and industry rank for Novadaq Technologies's EV-to-EBITDA or its related term are showing as below:
NVDQ's EV-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 16.18 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Novadaq Technologies EV-to-EBITDA Historical Data
The historical data trend for Novadaq Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Novadaq Technologies's EV-to-EBITDA
For the Diagnostics & Research subindustry, Novadaq Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novadaq Technologies's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Novadaq Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Novadaq Technologies's EV-to-EBITDA falls into.
Novadaq Technologies's current Enterprise Value is $660.94 Mil.
Novadaq Technologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Novadaq Technologies's PE Ratio for today is calculated as:
Novadaq Technologies's share price for today is $11.75.
Novadaq Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.970.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Novadaq Technologies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Novadaq Technologies (Novadaq Technologies) Business Description
Novadaq Technologies Inc was incorporated under the Canada Business Corporations Act on April 14, 2000. The Company develops and commercializes medical imaging and therapeutic devices for use in the operating room. It's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company's business activities are conducted through one segment, which consists of medical devices. Its product includes, SPY Elite, PINPOINT Endoscopic Fluorescence Imaging, FIREFLY System for Robotic Surgery, LUNA Fluorescence Angiography and CO2 HEART LASER System. The SPY Imaging System provides clinically relevant information that empowers surgeons to make informed critical decisions in the operating room. PINPOINT Endoscopic Fluorescence Imaging System combines all of the fluorescence imaging capabilities of SPY Imaging with the HD visible light imaging capabilities of a traditional endoscopic imaging system. FIREFLY system enables surgeons performing robotic surgery to benefit from fluorescence imaging, with initial use in applications ranging from urology to gynecology. LUNA fluorescence angiography enables clinicians to visually assess tissue perfusion in diabetic foot ulcers and non-healing wounds. The CO2 HEART LASER System consists of: the CO2 HEART LASER mobile console and the CO2 HEART LASER disposable hand pieces. The Company's intellectual property consists of 49 patent families representing 128 granted or allowed patents and 90 pending applications in various stages of review and prosecution.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVDQ has been successfully added to your 